The US Department of Justice (DOJ) has asked for more details on CVS’s proposed $8 billion deal to buy Signify Health, in a possible indication that the companies face a longer deal investigation, reported Reuters.
The deal, announced last month, was expected to face a tough antitrust review even though the two companies do not compete directly in any market, according to experts.
Large mergers and acquisitions have come under intense antitrust scrutiny, and lowering healthcare costs has been an important strategic mission for the Biden Administration.
Related: DOJ Sues To Block UnitedHealth’s Bid For Change Healthcare
UnitedHealth earlier this month completed its acquisition of Change Healthcare , after over a year of antitrust scrutiny.
Acquiring Signify Health will enable CVS, which operates a pharmacy chain, a health insurance business and offers pharmacy benefit management services, to provide further care management for at-home patients.
The deal is expected to close in the first half of 2023, CVS said in a filing on Thursday.
Signify offers technology and analytics to help with at-home care for patients. It has said its services can help identify potential health risks and gaps in care.
Featured News
FTC Files Suit Against Liquor Giant Southern Glazer’s Over Discount Disparities
Dec 12, 2024 by
CPI
Racing Rivals Accuse NASCAR of Retaliation in High-Stakes Antitrust Battle
Dec 12, 2024 by
CPI
Samsung Challenges Indian Antitrust Investigation, Calls Raid “Unlawful”
Dec 12, 2024 by
CPI
European Sites Criticize Google’s Compliance Efforts with DMA
Dec 12, 2024 by
CPI
Banco BPM Overcomes Regulatory Hurdle in $1.7 Billion Bid
Dec 12, 2024 by
CPI
Antitrust Mix by CPI
Coopetition in The Pharma Industry: Challenges for Antitrust
Dec 12, 2024 by
Juan Delgado & Lourdes Sosa
Symmetry and the Sixth Force: The Essential Role of Complements
Dec 12, 2024 by
Adam Brandenburger & Barry Nalebuff
ESG Collaborations in Light of European Antitrust Policy and Enforcement Trends
Dec 12, 2024 by
Christian Ritz, Julia Gingelmaier & Kyra Harmes
Antitrust Chronicle® – Co-opetition
Dec 11, 2024 by
CPI
Antitrust Chronicle® – Moats & Entrenchment
Nov 29, 2024 by
CPI